Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome

Autoimmunity Reviews

Volumn 12, Issue 2, 2012, Pages 313-317

  Mahler, Michael ^a   Norman, Gary L ^a   Meroni, Pier Luigi ^b   Khamashta, Munther ^c  

^a INOVA DIAGNOSTICS INC   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid syndrome; APS; Autoantibodies; Beta 2 glycoprotein 1; Domain 1

Indexed keywords

BETA 2 GLYCOPROTEIN 1 DOMAIN 1 ANTIBODY; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; EPITOPE; LIPOCORTIN 5; PROTHROMBIN; UNCLASSIFIED DRUG; VIMENTIN;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL FEATURE; CONFORMATIONAL TRANSITION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; REVIEW; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; EPITOPES; HUMANS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 84870255310     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.05.006     Document Type: Review

References (43)

1. Iverson G.M., Reddel S., Victoria E.J., Cockerill K.A., Wang Y.X., Marti-Renom M.A., et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002, 169:7097-7103.
2. McNeil H.P., Simpson R.J., Chesterman C.N., Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990, 87:4120-4124.
3. de Laat B., de Groot P.G. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep 2011, 13:70-76.
4. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011, 7:330-339.
5. Ruiz-Irastorza G., Crowther M., Branch W., Khamashta M.A. Antiphospholipid syndrome. Lancet 2010, 376:1498-1509.
6. Rodriguez-Garcia J.L., Bertolaccini M.L., Cuadrado M.J., Sanna G., Ateka-Barrutia O., Khamashta M.A. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS'). Ann Rheum Dis 2012, 71:242-244.
7. Sanmarco M. Clinical significance of antiphosphatidylethanolamine antibodies in the so-called "seronegative antiphospholipid syndrome". Autoimmun Rev 2009, 9:90-92.
8. Erkan D., Espinosa G., Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010, 10:74-79.
9. Meroni P.L., Shoenfeld Y. Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies. Autoimmun Rev 2008, 7:585-587.
10. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
11. Lozier J., Takahashi N., Putnam F.W. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci U S A 1984, 81:3640-3644.
12. de Groot P.G., Meijers J.C. beta(2) -Glycoprotein I: evolution, structure and function. J Thromb Haemost 2011, 9:1275-1284.
13. Feletar M., Ibanez D., Urowitz M.B., Gladman D.D. The impact of the 1997 update of the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus: what has been changed?. Arthritis Rheum 2003, 48:2067-2069.
14. Simmelink M.J., de Groot P.G., Derksen R.H. A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis. J Thromb Haemost 2003, 1:735-739.
15. Pengo V., Biasiolo A., Pegoraro C., Iliceto S. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004, 2:702-707.
16. Pierangeli S.S., de Groot P.G., Dlott J., Favaloro E., Harris E.N., Lakos G., et al. 'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus 2011, 20:182-190.
17. Lakos G., Favaloro E.J., Harris E.N., Meroni P.L., Tincani A., Wong R.C., et al. International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012, 64:1-10.
18. Bertolaccini M.L., Amengual O., Atsumi T., Binder W.L., de Laat B., Forastiero R., et al. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus 2011, 20:191-205.
19. Alessandri C., Conti F., Pendolino M., Mancini R., Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev 2011, 10:609-616.
20. Ortona E., Capozzi A., Colasanti T., Conti F., Alessandri C., Longo A., et al. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood 2010, 116:2960-2967.
21. George J., Gilburd B., Hojnik M., Levy Y., Langevitz P., Matsuura E., et al. Target recognition of beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of beta2GPI in antibody binding. J Immunol 1998, 160:3917-3923.
22. Yang C.D., Chen S.L., Shen N., Qi M., Xu F. Detection of anti-recombinant beta 2-glycoprotein 1 and anti-recombinant beta 2-glycoprotein 1 fifth-domain antibodies in sera from patients with systemic lupus erythematosus. Rheumatol Int 1998, 18:5-10.
23. Iverson G.M., Victoria E.J., Marquis D.M. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998, 95:15542-15546.
24. Arvieux J., Regnault V., Hachulla E., Darnige L., Roussel B., Bensa J.C. Heterogeneity and immunochemical properties of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost 1998, 80:393-398.
25. Iverson G.M., von Muhlen C.A., Staub H.L., Lassen A.J., Binder W., Norman G.L. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun 2006, 27:266-271.
26. Ioannou Y., Pericleous C., Giles I., Latchman D.S., Isenberg D.A., Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007, 56:280-290.
27. de Laat B., Derksen R.H., Urbanus R.T., de Groot P.G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005, 105:1540-1545.
28. de Laat B., van B.M., Urbanus R.T., Siregar B., de Groot P.G., Gebbink M.F., et al. Immune responses against domain I of beta(2)-glycoprotein I are driven by conformational changes: domain I of beta(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum 2011, 63:3960-3968.
29. Andreoli L., Nalli C., Motta M., Norman G.L., Shums Z., Encabo S., et al. Anti-beta-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile?. Ann Rheum Dis 2011, 70:380-383.
30. Nalli C., Andreoli L., Norman G.L., Shums Z., Binder W., Encabo S., et al. Antibodies versus Domain I of B2GPI as a Marker of Systemic Autoimmunity. 8th International Congress on Autoimmunity, Granada, Spain 2012.
31. de Laat B., Pengo V., Pabinger I., Musial J., Voskuyl A.E., Bultink I.E., et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009, 7:1767-1773.
32. Iverson G.M., Matsuura E., Victoria E.J., Cockerill K.A., Linnik M.D. The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA. J Autoimmun 2002, 18:289-297.
33. Pozzi N., Banzato A., Bettin S., Bison E., Pengo V., De F. V: Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1-64 of beta2-glycoprotein I. Protein Sci 2010, 19:1065-1078.
34. Banzato A., Pozzi N., Frasson R., De Filippis V., Ruffatti A., Bison E., et al. Antibodies to Domain I of beta(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thromb Res 2011, 128:583-586.
35. Mahler M., Radice A., Yang W., Bentow C., Seaman A., Bianchi L., et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta 2012, 413:719-726.
36. Otomo K., Atsumi T., Amengual O., Fujieda Y., Kato M., Oku K., et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012, 64:504-512.
37. Pengo V., Banzato A., Bison E., Bracco A., Denas G., Ruffatti A. What Have We Learned about Antiphospholipid Syndrome from Patients and Antiphospholipid Carrier Cohorts?. Semin Thromb Hemost Jun 2012, 38(4):322-327.
38. Ruffatti A., Tonello M., Visentin M.S., Bontadi A., Hoxha A., De C.S., et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011, 50:1684-1689.
39. Pengo V., Ruffatti A., Legnani C., Testa S., Fierro T., Marongiu F., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011, 118:4714-4718.
40. Kutteh W.H., Nelson V., Norman G.L. Anti-phosphatidylserine/prothrombin (PS/PT) antibodies in recurrent pregnancy loss 2011, American College of Gynecology, Washington.
41. Bossuyt X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009, 8:543-548.
42. Bozic B., Cucnik S., Kveder T., Rozman B. Avidity of anti-beta-2-glycoprotein I antibodies. Autoimmun Rev 2005, 4:303-308.
43. Ichikawa K., Tsutsumi A., Atsumi T., Matsuura E., Kobayashi S., Hughes G.R., et al. A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies. Arthritis Rheum 1999, 42:2461-2470.